- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Radiopharm (RADX) Sees Slight Pessimism From Analysts | 1 | Insider Monkey | ||
| Mo | Radiopharm Theranostics: 92 % der Probanden erreichen primären Endpunkt in RAD101-Studie | 4 | Investing.com Deutsch | ||
| RADIOPHARM THERANOSTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases | 6 | GlobeNewswire (USA) | ||
| Mo | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| So | RADIOPHARM THERANOSTICS LIMITED: RAD101 interim Phase 2b data - 92% achieve primary endpoint | 1 | ASX | ||
| Mi | RADIOPHARM THERANOSTICS LIMITED: Ceasing to be a substantial holder PH | 1 | ASX | ||
| 09.12. | RADIOPHARM THERANOSTICS LIMITED: Notice Under Section 708A | 1 | ASX | ||
| 09.12. | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | - | ASX | ||
| 09.12. | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | - | ASX | ||
| 09.12. | RADIOPHARM THERANOSTICS LIMITED: New Class Options Range of Units and Top 20 Holders | 1 | ASX | ||
| 04.12. | RADIOPHARM THERANOSTICS LIMITED: Application for quotation of securities - RAD | - | ASX | ||
| 04.12. | Radiopharm Theranostics Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.12. | RADIOPHARM THERANOSTICS LIMITED: Results of Meeting | - | ASX | ||
| 03.12. | RADIOPHARM THERANOSTICS LIMITED: Share purchase plan completed | - | ASX | ||
| 30.11. | RADIOPHARM THERANOSTICS LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 26.11. | Radiopharm Theranostics stock price target lowered to $13 at B.Riley | 1 | Investing.com | ||
| 25.11. | RADIOPHARM THERANOSTICS LIMITED: Notification of cessation of securities - RAD | - | ASX | ||
| 25.11. | RADIOPHARM THERANOSTICS LIMITED: Final Director's Interest Notice - PH | - | ASX | ||
| 25.11. | RADIOPHARM THERANOSTICS LIMITED: Final Director's Interest Notice - LA | - | ASX | ||
| 20.11. | RADIOPHARM THERANOSTICS LIMITED: Results of Meeting | 1 | ASX |
1 2 3 4 5 Weiter >>
102 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOME | 22,640 | +15,39 % | Immunome plans to offer $400 million in common stock shares | ||
| APOGEE THERAPEUTICS | 76,81 | -0,35 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| RECURSION PHARMACEUTICALS | 4,200 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,730 | -0,25 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 38,335 | -0,70 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| DISC MEDICINE | 92,00 | +0,12 % | H.C. Wainwright reiterates Buy rating on Disc Medicine stock | ||
| VERA THERAPEUTICS | 49,170 | -1,23 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ARTIVA BIOTHERAPEUTICS | 6,300 | 0,00 % | Artiva Biotherapeutics, Inc. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 19,010 | 0,00 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| KYVERNA THERAPEUTICS | 10,810 | 0,00 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome | Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 35,840 | +8,47 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| PRAXIS PRECISION MEDICINES | 276,42 | +2,77 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| BIONTECH | 79,95 | -1,05 % | BioNTech: Starke Studiennews - Aktie zieht an | Die Aktie von BioNTech kann zum Wochenstart deutlich zulegen. Gute News vom Wochenende zum Produktkandidaten BNT316 bei Lungenkrebs unterstützen die Aktie. Für einen charttechnischen Befreiungsschlag... ► Artikel lesen | |
| LENZ THERAPEUTICS | 17,080 | -5,84 % | LENZ Therapeutics, Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 40,230 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen |
RADIOPHARM THERANOSTICS LIMITED ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 10,630 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RADIOPHARM THERANOSTICS LIMITED ADR finden Sie auf Wallstreet Online.